Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Blocking the production of CHD4 protein may help increase effectiveness of AML treatments

Preclinical experiments led by a team of researchers at VCU Massey Cancer Center have shown that blocking the production of a protein known as chromodomain helicase DNA-binding protein 4 (CHD4) may help increase the effectiveness of first-line treatments for acute myeloid leukemia (AML), a particularly lethal blood cancer that is increasing in incidence among older adults.

14 Oct 2015

Bacterium that causes Q fever associated with increased risk of lymphoma

The bacterium that causes Q fever, an infectious disease that humans contract from animals, is associated with an increased risk of lymphoma, according to a study published online today in Blood, the Journal of the American Society of Hematology.

13 Oct 2015

Malaria protein could one day help stop cancer

Scientists at the University of British Columbia, Vancouver Coastal Health and the BC Cancer Agency have discovered a protein from malaria that could one day help stop cancer in its tracks.

13 Oct 2015

Danish researchers face possible breakthrough in fight against cancer

The hunt for a vaccine against malaria in pregnant women has provided an unexpected side benefit for Danish researchers, namely what appears to be an effective weapon against cancer. The scientists behind the vaccine aim for tests on humans within four years.

13 Oct 2015

Penn study forms basis for new treatment approaches for Sezary syndrome

Sezary syndrome (SS), an aggressive leukemia of mature T cells, is more complicated at a molecular level than ever suspected, according to investigators from the Perelman School of Medicine at the University of Pennsylvania.

8 Oct 2015

Dr. Paul Liu named 2015 Distinguished Alumnus for contributions to leukemia research

In his laboratory in the National Human Genome Research Institute in Bethesda, Md., Paul Liu, M.D., Ph.D., is working on targeted treatments for leukemia, a life-threatening blood cancer.

8 Oct 2015

IQWiG finds no added benefit for ceritinib drug in adults with NSCLC

The drug ceritinib (trade name: Zykadia) has been approved since May 2015 for the treatment of adults with non-small cell lung cancer (NSCLC). It is an option when certain changes in the cancer cells (anaplastic lymphoma kinase-positive) stimulate tumour growth and patients have already been pretreated with crizotinib.

7 Oct 2015

New smartphone-based device can reliably perform molecular diagnoses at low cost

NIBIB-funded researchers at the Massachusetts General Hospital have developed a smartphone-based device that can reliably carry out molecular diagnoses in under an hour for approximately two dollars per patient. The device could enable point-of-care cancer diagnostics in low- to middle-income or remote areas, which often have high rates of mortality from cancer due to missed opportunities for treatment.

6 Oct 2015

Researchers reveal how varied genetic background influences tumour differences

Researchers from Uppsala University, Sweden, and the Broad Institute, USA, have identified both similarities and differences between a single tumour type in multiple dogs breeds; a finding they believe parallels the situation in the cancer of human patients.

30 Sep 2015

Novel portable device counts white blood cells in real time

A novel way to count white blood cells without a blood test, simply by applying a small device on the fingertip, is being developed by a team of young bioengineers. The technology, that combines an optical sensor with algorithms, has already three prototypes on the go and is specially designed to be used on chemotherapy patients, who could know their immune system levels in real time. It could also serve to detect serious infections.

30 Sep 2015

New study finds that serum miRNA profiles change as myeloma progresses

Virtually all patients who develop myeloma have an asymptomatic disease called monoclonal gammopathy of undetermined significance (MGUS) in the years before the onset of myeloma. The five-year relative survival rate for myeloma is 69% for patients diagnosed with stage I or localized disease, compared with 45% for patients with advanced cancer.

30 Sep 2015

Cancer treatment does not affect pregnancy outcome, shows new study

Women who are pregnant when diagnosed with cancer can start treatment for their disease immediately and do not need to terminate their pregnancy due to worries over the effects of therapy on the development of their child.

29 Sep 2015

EUROCARE 5 study shows large variations in blood cancer patients' survival in Europe

Comparisons of cancer patients' survival and care in Europe up to 2007 show that although more patients are surviving for at least five years after diagnosis, there are large variations between countries, which are particularly significant in cancers of the blood.

26 Sep 2015

Protein-coding gene identified as tumor suppressor for acute myeloid leukemia

A protein-coding gene called hnRNP K has been identified as a tumor suppressor for acute myeloid leukemia (AML), a finding that could be important for investigating how best to target treatment of a blood cancer striking mostly older individuals.

24 Sep 2015

JRC, CERN to explore potential of accelerator-driven method for producing targeted alpha therapy for cancer

A novel, accelerator-driven method could produce nuclides for targeted alpha therapy of cancer in practically unlimited amounts, overcoming current obstacles for its wider use due to a limited production of alpha-emitters. The JRC and the Conseil Européen pour la Recherche Nucléaire have embarked to explore the potential of the jointly proposed method.

24 Sep 2015

Hyperbaric oxygen therapy improves outcomes of umbilical cord blood transplant patients

For the past 27 years, cord blood transplants have been a life-saving treatment option for thousands of people with leukemia, non-Hodgkins lymphoma, Hodgkins disease and myelodysplastic disorders. Cord blood helps replace cancerous blood cells and replenish a patient's own bone marrow and immune system. Even with its success, researchers are continually looking for ways to improve the transplant process and increase cure rates.

24 Sep 2015

Bretuximab vedotin safe, effective for older Hodgkin lymphoma patients unfit for chemotherapy

A study, published online in Blood, the Journal of the American Society of Hematology, reports that bretuximab vedotin is an effective and safe first course of treatment for older Hodgkin lymphoma patients unfit for chemotherapy.

22 Sep 2015

Cancer-causing gene disrupts internal rhythm, metabolic pathways in cancer cells

Myc is a cancer-causing gene responsible for disrupting the normal 24-hour internal rhythm and metabolic pathways in cancer cells, found a team led by researchers from the Perelman School of Medicine at the University of Pennsylvania. Postdoctoral fellow Brian Altman, PhD, and doctoral student Annie Hsieh, MD, both from the lab of senior author Chi Van Dang, MD, PhD, director Abramson Cancer Center, study body clock proteins associated with cancer cells.

18 Sep 2015

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen and Xencor, Inc. announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation.

16 Sep 2015

Scientists find how cells adapt to overcome cancer drugs

CANCER RESEARCH UK scientists have found how cells adapt to overcome cancer drugs designed to interfere with their genetic controls, according to a study published today (Wednesday) in Epigenetics and Chromatin.

16 Sep 2015

Lymphoma News and Research

Further Reading

Blocking the production of CHD4 protein may help increase effectiveness of AML treatments

Bacterium that causes Q fever associated with increased risk of lymphoma

Malaria protein could one day help stop cancer

Danish researchers face possible breakthrough in fight against cancer

Penn study forms basis for new treatment approaches for Sezary syndrome

Dr. Paul Liu named 2015 Distinguished Alumnus for contributions to leukemia research

IQWiG finds no added benefit for ceritinib drug in adults with NSCLC

New smartphone-based device can reliably perform molecular diagnoses at low cost

Researchers reveal how varied genetic background influences tumour differences

Novel portable device counts white blood cells in real time

New study finds that serum miRNA profiles change as myeloma progresses

Cancer treatment does not affect pregnancy outcome, shows new study

EUROCARE 5 study shows large variations in blood cancer patients' survival in Europe

Protein-coding gene identified as tumor suppressor for acute myeloid leukemia

JRC, CERN to explore potential of accelerator-driven method for producing targeted alpha therapy for cancer

Hyperbaric oxygen therapy improves outcomes of umbilical cord blood transplant patients

Bretuximab vedotin safe, effective for older Hodgkin lymphoma patients unfit for chemotherapy

Cancer-causing gene disrupts internal rhythm, metabolic pathways in cancer cells

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Scientists find how cells adapt to overcome cancer drugs

Everything you should know about lymphoma eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News